Pamicogrel is a cyclooxygenase inhibitor that was under development for its anti-platelet-aggregation effects.[1][2]

Pamicogrel
Names
Preferred IUPAC name
Ethyl {2-[4,5-bis(4-methoxyphenyl)-1,3-thiazol-2-yl]-1H-pyrrol-1-yl}acetate
Other names
KB 3022, Paminate
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C25H24N2O4S/c1-4-31-22(28)16-27-15-5-6-21(27)25-26-23(17-7-11-19(29-2)12-8-17)24(32-25)18-9-13-20(30-3)14-10-18/h5-15H,4,16H2,1-3H3
    Key: ISCHOARKJADAKJ-UHFFFAOYSA-N
  • InChI=1/C25H24N2O4S/c1-4-31-22(28)16-27-15-5-6-21(27)25-26-23(17-7-11-19(29-2)12-8-17)24(32-25)18-9-13-20(30-3)14-10-18/h5-15H,4,16H2,1-3H3
    Key: ISCHOARKJADAKJ-UHFFFAOYAC
  • CCOC(=O)CN1C=CC=C1C2=NC(=C(S2)C3=CC=C(C=C3)OC)C4=CC=C(C=C4)OC
Properties
C25H24N2O4S
Molar mass 448.54 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

References

edit
  1. ^ Light P (September 1999). "Pamicogrel (Kanebo)". IDrugs. 2 (9): 938–42. PMID 16121308.
  2. ^ "Pamicogrel inhibits platelet aggregation". Inpharma Weekly. 1272 (1): 11. January 2001. doi:10.2165/00128413-200112720-00021. S2CID 195132149.
edit